ASTEC Q2 : CONS NET LOSS WIDENS TO ₹37.4 CR (YOY). WEAK (ON 1ST LOOK)

Total income down 3% at ₹72.6 Cr (YOY); H1 down 6% at ₹156.9 Cr. Ebitda negative at ₹19.2 Cr v negative ₹5.6 Cr (YOY). Reported loss after tax ₹37.4 Cr v ₹24.4 Cr (YOY); H1 loss ₹56.1 Cr v ₹57.4 Cr. Enterprise revenue ₹57 Cr, down 6%; CDMO up 15% at ₹15 Cr. Exports down 30% at ₹28.9 Cr; domestic up 32% at ₹43.1 Cr. Caution: inventory write-down of ₹3 Cr to net realisable value.

Astec Lifesciences Ltd

Open attachment

← Back to feed